These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 21769421)
1. Gene expression of vasoactive intestinal peptide receptors in human lung cancer. Szilasi M; Buglyo A; Treszl A; Kiss L; Schally AV; Halmos G Int J Oncol; 2011 Oct; 39(4):1019-24. PubMed ID: 21769421 [TBL] [Abstract][Full Text] [Related]
2. Down-regulation of vasoactive intestinal peptide and altered expression of its receptors in rat diabetic cardiomyopathy. Dvoráková MC; Pfeil U; Kuncová J; Svíglerová J; Galvis G; Krasteva G; König P; Grau V; Slavíková J; Kummer W Cell Tissue Res; 2006 Mar; 323(3):383-93. PubMed ID: 16344947 [TBL] [Abstract][Full Text] [Related]
3. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation. St Hilaire RC; Murthy SN; Kadowitz PJ; Jeter JR Peptides; 2010 Aug; 31(8):1517-22. PubMed ID: 20452385 [TBL] [Abstract][Full Text] [Related]
4. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary. Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238 [TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463 [TBL] [Abstract][Full Text] [Related]
6. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue. García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382 [TBL] [Abstract][Full Text] [Related]
7. Location and function of VPAC1, VPAC2 and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries. Grant S; Lutz EM; McPhaden AR; Wadsworth RM J Cereb Blood Flow Metab; 2006 Jan; 26(1):58-67. PubMed ID: 15959462 [TBL] [Abstract][Full Text] [Related]
8. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701 [TBL] [Abstract][Full Text] [Related]
9. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland. Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance. Fernández-Martínez AB; Carmena MJ; Arenas MI; Bajo AM; Prieto JC; Sánchez-Chapado M Histol Histopathol; 2012 Aug; 27(8):1093-101. PubMed ID: 22763881 [TBL] [Abstract][Full Text] [Related]
12. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis. Yadav M; Huang MC; Goetzl EJ Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288 [TBL] [Abstract][Full Text] [Related]
13. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects. Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439 [TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells. Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945 [TBL] [Abstract][Full Text] [Related]
15. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Sun W; Hong J; Zang YC; Liu X; Zhang JZ Int Immunol; 2006 Dec; 18(12):1691-700. PubMed ID: 17077178 [TBL] [Abstract][Full Text] [Related]
16. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies. Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599 [TBL] [Abstract][Full Text] [Related]
17. Development-related splicing regulates pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in the retina. Lakk M; Szabó B; Völgyi B; Gábriel R; Dénes V Invest Ophthalmol Vis Sci; 2012 Nov; 53(12):7825-32. PubMed ID: 23099490 [TBL] [Abstract][Full Text] [Related]
18. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Juarranz Y; Gutiérrez-Cañas I; Santiago B; Carrión M; Pablos JL; Gomariz RP Arthritis Rheum; 2008 Apr; 58(4):1086-95. PubMed ID: 18383383 [TBL] [Abstract][Full Text] [Related]
19. Mechanisms of vasoactive intestinal peptide-elicited coronary vasodilation in the isolated perfused rat heart. Sawmiller DR; Ashtari M; Urueta H; Leschinsky M; Henning RJ Neuropeptides; 2006 Oct; 40(5):349-55. PubMed ID: 17030371 [TBL] [Abstract][Full Text] [Related]
20. Alterations of vasoactive intestinal polypeptide receptors in allergic rhinitis. Kim DH; Park IH; Cho JS; Lee YM; Choi H; Lee HM Am J Rhinol Allergy; 2011; 25(1):e44-7. PubMed ID: 21711977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]